SCYNEXIS INC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SCYNEXIS, Inc. on April 10, 2016, covering events occurring on April 10 and April 11, 2016. The filing details the termination of a previous sales agreement and the execution of a new equity offering program.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the terms of a new equity offering:
- Offering Capacity: Up to $40,000,000 of common stock.
- Sales Agent Commission: 3.0% of the gross sales price of shares sold.
- Estimated Expenses: Approximately $135,000 (excluding commissions).
- Shares Sold to Date: No shares were sold under the terminated agreement with Cowen and Company, LLC.
Material Changes
The Company terminated its "at-the-market" (ATM) Sales Agreement with Cowen and Company, LLC, dated November 11, 2015, on April 10, 2016. Subsequently, on April 11, 2016, the Company entered into a new Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell up to $40,000,000 of common stock through an ATM program.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. Key terms and contingencies of the new agreement include:
- Flexibility: The Company is not obligated to sell any shares and may instruct the agent not to sell if prices are below a designated level.
- Termination: The agreement terminates upon the sale of all shares or by notice from either party.
- Indemnification: The Company agreed to indemnify Cantor Fitzgerald against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the current market price of SCYNEXIS common stock to assess the potential dilution impact of a $40,000,000 offering.
- Review the Company's cash position in the most recent 10-Q or 10-K to determine the immediate necessity of raising capital.
- Confirm the status of the Form S-3 Registration Statement (File No. 333-207705) referenced in the filing.
- Monitor future filings for actual share sales and proceeds generated under the new Cantor Fitzgerald agreement.